- Home
- SEVN vs NGEN Comparison
SEVN vs NGEN Comparison
Compare SEVN & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SEVN | NGEN |
|---|---|---|
| Founded | 1986 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 9 |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.6M | 175.1M |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | SEVN | NGEN |
|---|---|---|
| Price | $8.49 | $1.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $10.50 | ★ $18.00 |
| AVG Volume (30 Days) | 69.4K | ★ 1.2M |
| Earning Date | 04-28-2026 | 04-02-2026 |
| Dividend Yield | ★ 13.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $29,383,000.00 | N/A |
| Revenue This Year | $27.75 | N/A |
| Revenue Next Year | $4.06 | N/A |
| P/E Ratio | $44.63 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.90 | $1.87 |
| 52 Week High | $12.85 | $5.93 |
Technical Indicators
Market Signals| Indicator | SEVN | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 53.05 | 25.23 |
| Support Level | $8.33 | N/A |
| Resistance Level | $8.95 | $4.52 |
| Average True Range (ATR) | 0.18 | 0.15 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 48.80 | 1.05 |
Price Performance
Historical ComparisonAbout SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.